Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 37Squamous Cell Carcinoma of Head and Neck 19Head and Neck Neoplasms 17Nasopharyngeal Neoplasms 7Salivary Gland Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Esthesioneuroblastoma, Olfactory 3Esophageal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Hypopharyngeal Neoplasms 2Gallbladder Neoplasms 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Skin Neoplasms 1Neoplasms, Unknown Primary 1

Interventions

Radiotherapy, Intensity-Modulated 1Immune Checkpoint Inhibitors 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Cancinoma (NPC) × Capecitabine × Head & Neck × Clear all
NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
516 enrolled
Head & Neck

Nasopharyngeal Cancinoma (NPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡